Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 783

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 783
---
 As certain clinical milestones are met, the Company shall owe additional fees, ranging from $ 187,500upon a Phase 1 trial initiation to $ 1,250,000upon FDA approval. In addition, if there is a change of control, the Company shall owe 25% of the transaction fee that was paid to the investment bank. If the Company enters into a sublicense of the technology, these institutions shall receive a low double-digit percentage of the sublicense income. There are single digit royalties on net sales of products that use the patented technology, along with minimum royalties if minimum sales targets are not reached. If certain clinical trial milestones are not reached within a certainperiod, without being extended by the Company, then Moffitt has the right to terminate the license agreement. F- 61

TUHURA BIOSCIENCES, INC. AND SUBSIDIARY Notes to the consolidated financial statements For the years ended December 31, 2023, and 2022 Note 13—Subsequent events Subsequent Events– The Company has evaluated subsequent eventsthrough April 1, 2024 in connectionwith the preparation of these financial statements, which is the date the financial statements were available to be issued. Convertible promissory notes On March, 21, 2024, the Company amended the terms in the event that the Company enters into definitive merger agreement on or before May 15, 2024, for a reverse merger transaction with a publicly listed company. The notes will then, immediately prior to the closing of such reverse merger transaction, convert automatically into a number of shares of common stock of the applicable public company, equal to the Conversion Amount divided by Sixty Eight Cents ($ 0.68) (which shall be subject to adjustment for any stock splits, reverse stock split, or the like occurring after the issuance of the Notes and before the conversion of the Notes). Extension of office space lease On March 22, 2024, The Company entered into a 25-monthoffice lease extension commencing March 1, 2024 with total fixed monthly lease payments of approximately $ 14,000. The lease extension is for office space where the Company is currently located in Tampa, Florida. F-6 2

TUHURA BIOSCIENCES, INC AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS As of September 30, 2024 (Unaudited), and December 31, 2023

|                                             |     |   |     Unaudited